---
title: "Humana Company Profile"
description: "Educational business and investor-research dossier for Humana, including business-model analysis, economics, metrics, risks, monitoring questions."
canonical: https://www.getswoopr.com/stocks/companies/humana/
source: "Swoopr Investment: https://www.getswoopr.com"
---

# Humana Company Profile

## Direct answer

Humana (HUM) is a Health Care company and a constituent of the S&P 500 Equal Weight Index.

This guide covers Humana's business model, financial metrics, competitive position, risk factors, and index membership as an educational business primer. It does not constitute personalized investment advice or a buy, sell, or price-target recommendation.

## What Do the Latest SEC Filings Show for Humana?

These are figures Humana reported in its own SEC filings, read from the SEC's XBRL data, so the page has a fixed starting point before any of the research questions below. They describe reported history and are not a forecast.

| Item | As reported |
| --- | --- |
| Ticker symbol | HUM |
| SEC industry classification | 6324, Hospital & Medical Service Plans |
| Fiscal year ends | December 31 |
| Latest fiscal year reported | FY2025, ended December 31, 2025 |
| Revenue | $130 billion |
| Net income (loss) | $1.2 billion |
| Operating cash flow | $921 million |
| Cash and cash equivalents | $4.2 billion |

Source: [SEC EDGAR: HUMANA INC Form 10-K filed February 19, 2026](https://www.sec.gov/Archives/edgar/data/49071/000004907126000009/hum-20251231.htm).

## Company Snapshot

| Field | Value |
| --- | --- |
| Company | Humana |
| Security line(s) | HUM |
| SEC CIK | 49071 |
| GICS sector | Health Care |
| GICS sub-industry | Managed Health Care |
| Founded / lineage | 1961 |
| S&P 500 addition date | 2012-12-10 |
| S&P 500 Equal Weight status | Current company constituent as of 2026-09-15 |
| Equal Weight target concept | Equal company weight at quarterly rebalance; nominally 0.20% when there are 500 companies |
| Canonical Swoopr company URL | `/stocks/companies/humana/` |

## What the Company Does

The most defensible high-level description of Humana begins with its GICS placement in Managed Health Care. In practical terms, Humana participates in an industry where a company generally delivers, finances, administers, or distributes healthcare services and products across insurers, providers, patients, pharmacies, and care settings. That is an analytical starting point, not a substitute for Humana's own segment disclosure. Use Humana's latest annual report to name its actual reported segments, economically important products and services, brands, customer groups, and geographies. Where Humana reports businesses that cross GICS boundaries, keep those distinctions rather than forcing every activity into the Managed Health Care label. When researching Humana, the key question is: **what operating activity causes a customer to pay the company?** Answer it as a revenue tree rather than a marketing description. Start with the company's major reported business lines, connect each line to its paying customer, identify the unit that is sold or monetized, then identify whether the economics are recurring, transactional, cyclical, usage-based, regulated, project-based, volume-driven, or spread-driven for Humana. This turns a company description into a usable investment model.

## How the Company Makes Money

The business-model lens that fits Humana best is a healthcare-services, managed-care, facility, pharmacy, or distribution model. The variables to look at first are membership or patient volume, utilization, reimbursement rates, medical cost trends, script or distribution volume, and capacity and payer mix. These are industry mechanisms, not Humana's reported KPIs, so map them to the metrics Humana actually discloses. For each material revenue line at Humana, check which mechanism drives it, how pricing works, whether customers repeat, and whether the line carries a different margin or capital profile. Revenue quality matters as much as revenue growth. When reviewing Humana, separate growth from more customers or units from growth driven by price, mix, acquisitions, foreign exchange, accounting presentation, or temporary industry conditions. Then ask whether added revenue needs proportional new capital, inventory, labor, marketing, or fixed assets. The answer shows whether growth at Humana can compound with attractive cash economics or itself consumes substantial capital.

## Revenue Engine

The checklist below lists operating variables common in this industry. They are industry-level ideas, not reported figures, so confirm which ones Humana discloses as KPIs in its latest annual report (Form 10-K), and compare them with Humana's earnings materials.

- **Membership Or Patient Volume:** test direction, cause, revenue sensitivity, margin effect, and whether the change is durable or cyclical.

- **Utilization:** test direction, cause, revenue sensitivity, margin effect, and whether the change is durable or cyclical.

- **Reimbursement Rates:** test direction, cause, revenue sensitivity, margin effect, and whether the change is durable or cyclical.

- **Medical Cost Trends:** test direction, cause, revenue sensitivity, margin effect, and whether the change is durable or cyclical.

- **Script Or Distribution Volume:** test direction, cause, revenue sensitivity, margin effect, and whether the change is durable or cyclical.

- **Capacity And Payer Mix:** test direction, cause, revenue sensitivity, margin effect, and whether the change is durable or cyclical.

## Business Segments

Humana's exact segment names and reported segment financials come from its latest filing. For each reportable segment, check what it sells, who buys it, how it is priced, its growth and margin characteristics, important geographies, strategic role, and specific risks for Humana. If management changes segment reporting, compare periods on one consistent definition and note where the restatement begins, rather than splicing unlike periods together for Humana. Until a filing-derived segment table is available, avoid treating the consolidated Managed Health Care classification as if it described every activity. Humana may contain businesses with very different cyclicality and capital intensity. The most useful segment analysis often identifies which segment contributes disproportionate profit or cash flow, which segment consumes the most capital, and which segment carries the highest expectations for future growth for Humana.

## Products, Services and Business Lines

This page covers only the economically significant Humana products, services, platforms, brands and franchises. Each item should be tied to a reportable business line and a monetization mechanism for Humana. Avoid an exhaustive catalog copied from a corporate website. The useful questions are whether an offering is a gateway product, a recurring revenue source, a high-margin add-on, a regulated necessity, a commodity-like product, or a strategic product that influences customer retention elsewhere in the portfolio for Humana.

## Customers and Buying Behavior

The relevant customer universe for this industry includes patients, employers, government programs, health plans, providers, pharmacies, manufacturers, and care organizations depending on the business. For Humana, the useful questions are which of those customer groups actually matter, whether a small number of customers represent concentration risk, how long purchasing decisions take, who controls the budget, and what makes a customer renew, reorder, switch, or delay purchases. Customer economics often explain why two companies in the same sub-industry can have very different margins and volatility for Humana. A durable customer relationship can show up through contracts, subscriptions, installed-base dependence, integration costs, distribution access, regulatory qualification, brand preference, or operational reliability for Humana. Those mechanisms must be evidenced for Humana; simply saying the company has “loyal customers” is not sufficient. The monitoring framework should watch for weakening retention, lower wallet share, rising incentives, longer sales cycles, or adverse changes in customer concentration for Humana.

## Geographic Exposure

Do not assume Humana's geographic revenue mirrors where it is headquartered. Humana's latest annual report (Form 10-K) shows, when disclosed, how revenue, assets, manufacturing, sourcing, regulatory exposure, and major customers are spread across regions. Geography matters because exchange rates, tariffs, export controls, taxes, local competition, political risk, and supply-chain concentration can change the economics even when overall demand for Humana is stable.

## Company Economics

For a Managed Health Care business, the core cost structure often includes medical claims or clinical labor, purchased pharmaceuticals/supplies, facility expense, technology, and regulatory compliance. When reviewing Humana, separate fixed from variable costs and distinguish accounting expenses from cash investment. Then examine operating leverage: if revenue rises by 10%, which costs rise nearly in line, which lag, and which may step up after capacity thresholds for Humana? The same exercise should be repeated in reverse for a downturn because downside operating leverage is often more important than upside leverage for Humana. Capital intensity is equally important. Humana can report attractive operating margins while requiring large amounts of working capital, plant, equipment, acquired intangibles, capitalized software, regulatory capital, or other reinvestment. Humana's page should therefore reconcile earnings with cash generation and explain which investments are maintenance requirements versus discretionary growth spending.

## Financial Statement Guide

### Income statement

Start with the revenue lines and expense categories that reflect membership or patient volume, utilization, and reimbursement rates. Separate organic operating change from acquisitions, divestitures, foreign exchange, accounting reclassifications, and unusual items for Humana. Margin analysis should show whether changes come from price, mix, volume, productivity, input costs, or overhead absorption for Humana.

### Balance sheet

Identify the assets and liabilities that make the a healthcare-services, managed-care, facility, pharmacy, or distribution model work. For Humana, focus on working capital, debt, goodwill and acquired intangibles, inventory or receivables where material, pension or insurance obligations where applicable, and any industry-specific capital or reserve requirements.

### Cash flow statement

Reconcile reported earnings to operating cash flow and then to free cash flow after economically necessary capital expenditures for Humana. Watch working-capital swings, restructuring cash costs, acquisition spending, stock-based compensation, and other items that can make a single period look unusually strong or weak for Humana.

### Capital expenditure and reinvestment

Determine how much spending merely maintains the existing earnings base and how much expands capacity or capabilities for Humana. The distinction is especially important when Humana's growth narrative depends on new facilities, networks, software, R&D, acquisitions, or customer acquisition.

## Metrics That Matter Most

These are the measures analysts commonly use to judge a business like Humana. Look each one up in Humana's latest annual report (Form 10-K) and quarterly filings (Form 10-Q); companies define some of them differently, so compare like with like.

| Metric | What it measures and why it matters | Where to look |
| --- | --- | --- |
| Membership Or Patient Volume | The number of members enrolled in a plan or patients served, or related visit and admission counts, over a period. Shows demand and scale for health related services. Volume must be read with reimbursement rates and the mix of care provided. | MD&A and earnings releases of healthcare firms. It is company defined, so check how members and patients are counted. |
| Medical Cost Ratio Where Relevant | Medical benefits paid divided by premium revenue for a health insurer. It is also called the medical loss ratio and shows the share of premiums spent on care. A lower ratio leaves more for administration and profit, while a higher one can signal rising care costs. Regulations may set minimum levels in some markets. | Health insurer MD&A, segment disclosures and earnings releases. Check how the company defines medical costs and premiums. |
| Same-Facility Growth | Growth in revenue or admissions at facilities operated in both comparison periods, excluding acquired, opened or closed facilities. Separates growth in existing operations from expansion by acquisition. Definitions of the comparable set differ by company. | MD&A and earnings releases. It is a company defined operating metric, so check the comparison rules. |
| Reimbursement/Payer Mix | The split of revenue by who pays for care or products, such as government programs, commercial insurers and patients, along with the rates they pay. Different payers pay different rates, so mix shifts can change margins. Policy changes in government programs can have large effects. | Revenue notes and MD&A payer breakdown in the annual report, plus risk factors on reimbursement. Categories are company defined. |
| Labor Cost | Total spending on wages, benefits and contract labor, often shown as a share of revenue. A large cost for service businesses, so changes strongly affect margins. Wage inflation and staffing levels both influence it. | Income statement lines, expense breakdowns in MD&A and notes. Whether contract labor is included varies by company. |
| Script/Distribution Volume | The number of prescriptions filled or the quantity of products distributed through a pharmacy or wholesale network in a period. Volume drives revenue for pharmacies and distributors. Growth can reflect share gains or industry trends, while margin per script may move differently. | Earnings releases, MD&A and segment disclosures. Prescription counts may be adjusted, such as for day supply, so check the definition. |
| Operating Margin | Operating income as a share of revenue, showing how much of each sales dollar remains after operating costs but before interest and taxes. Tracks pricing power and cost control. Rising margins suggest improving efficiency, though one-time charges or accounting changes can move it. | Calculated from the income statement. Adjusted versions in earnings releases are non-GAAP, so check the reconciliation and the company's definition. |
| Cash Flow | Cash moving into and out of a company in a period, reported across operating, investing and financing activities. Shows whether earnings are backed by actual cash and how the business funds itself. Timing and working capital can distort single periods. | Statement of cash flows in the Form 10-K and Form 10-Q, with discussion in MD&A. |
| Working Capital | Commonly defined as current assets minus current liabilities. Some companies use an operating version that excludes cash and debt. It shows whether a company can fund near term obligations and how much cash is tied up in operations. Swings can reflect timing rather than lasting change. | Balance sheet, with changes shown in the cash flow statement and explained in MD&A liquidity discussion. |
| Regulatory Quality Metrics | Measures used by regulators or payers to assess performance, such as quality ratings, safety records, inspection results or compliance outcomes. Results can affect payments, licenses or reputation. Poor scores tend to bring penalties or lost revenue, while good ones can support growth. | Annual report business and risk sections, regulator websites and company disclosures. Confirm which rating system applies and its date. |

## Competitive Position

Potential sources of competitive durability in this industry include scale, provider/payer networks, distribution density, data, local market position, and regulatory expertise. For Humana, a claimed advantage is only meaningful when tied to evidence: better retention, structurally lower costs, stronger unit economics, sustained share, premium pricing, shorter payback, higher utilization, superior reliability, or another measurable outcome. A moat claim without a mechanism and an observable consequence is not persuasive for Humana. A useful starting peer set inside the current index is [AbbVie](https://www.getswoopr.com/stocks/companies/abbvie/), [Abbott Laboratories](https://www.getswoopr.com/stocks/companies/abbott-laboratories/), [Agilent Technologies](https://www.getswoopr.com/stocks/companies/agilent-technologies/), [Align Technology](https://www.getswoopr.com/stocks/companies/align-technology/), [Amgen](https://www.getswoopr.com/stocks/companies/amgen/), [Centene Corporation](https://www.getswoopr.com/stocks/companies/centene-corporation/). This is an **index peer set**, not a claim that every named company is a direct competitor in every product line for Humana. A complete competitor analysis separates direct product competitors, substitute technologies, vertically integrated customers and suppliers, and companies that compete primarily for capital or distribution for Humana.

### Index peer comparison framework

| Peer | Why compare it | What to verify |
| --- | --- | --- |
| [AbbVie](https://www.getswoopr.com/stocks/companies/abbvie/) | Current S&P 500 peer classified in Biotechnology | Actual product overlap, customer overlap, margins, capital intensity, and geographic mix |
| [Abbott Laboratories](https://www.getswoopr.com/stocks/companies/abbott-laboratories/) | Current S&P 500 peer classified in Health Care Equipment | Actual product overlap, customer overlap, margins, capital intensity, and geographic mix |
| [Agilent Technologies](https://www.getswoopr.com/stocks/companies/agilent-technologies/) | Current S&P 500 peer classified in Life Sciences Tools & Services | Actual product overlap, customer overlap, margins, capital intensity, and geographic mix |
| [Align Technology](https://www.getswoopr.com/stocks/companies/align-technology/) | Current S&P 500 peer classified in Health Care Supplies | Actual product overlap, customer overlap, margins, capital intensity, and geographic mix |
| [Amgen](https://www.getswoopr.com/stocks/companies/amgen/) | Current S&P 500 peer classified in Biotechnology | Actual product overlap, customer overlap, margins, capital intensity, and geographic mix |
| [Centene Corporation](https://www.getswoopr.com/stocks/companies/centene-corporation/) | Current S&P 500 peer classified in Managed Health Care | Actual product overlap, customer overlap, margins, capital intensity, and geographic mix |

## Industry Position

Humana should be analyzed inside the structure of the Managed Health Care industry rather than in isolation. Map concentration, barriers to entry, buyer power, supplier power, substitution risk, capital requirements, regulation, technology change, and cyclicality for Humana. Then identify where Humana sits on the spectrum from price taker to differentiated supplier. This industry map is especially useful when Humana’s own results look strong: it helps determine whether the improvement reflects company-specific execution or a favorable cycle lifting most participants.

## Supply Chain and Dependencies

An initial supply-chain map for this industry connects drug/device manufacturers, providers, payers, pharmacies, employees/clinicians, and patients. The production Humana page should identify material single-source dependencies, constrained inputs, outsourced manufacturing or service dependencies, logistics bottlenecks, regulated interfaces, and customer concentration. The strongest supply-chain analysis identifies not only who supplies whom but also where bargaining power sits and which participant absorbs volatility when supply or demand changes for Humana.

## Economic Sensitivity

The macro variables most worth testing for this business model are employment, healthcare utilization, government budgets, wage inflation, demographics, and drug spending. These are hypotheses, not a claim that every variable has equal influence on Humana. Link each selected indicator to a specific transmission mechanism - for example, higher rates changing financing costs, weaker employment changing demand or credit, or industrial production changing order volumes for Humana. Remove macro indicators that do not have a defensible causal path to Humana's economics.

## Company History

Registry data records Humana's founding or corporate lineage as **1961** and its S&P 500 addition date as **2012-12-10**. Those two dates are only anchors. A publishable history should be built from issuer and SEC sources and focus on events that changed the economic identity of Humana: founding, major product or market entries, mergers, divestitures, restructurings, leadership transitions, regulatory events, crises, and strategic pivots. Avoid trivia that does not explain today’s business.

### Verified timeline anchors

- **1961:** Founding or corporate-lineage date recorded in the constituent metadata source. Verify nuanced predecessor history against issuer materials.

- **2012-12-10:** Humana security line `HUM` entered the S&P 500 according to the constituent registry used for this snapshot.

- **2026-09-15:** Humana is treated as a current constituent company of the S&P 500 Equal Weight Index snapshot used by Swoopr.

## Capital Allocation

Evaluate Humana's capital allocation as a hierarchy: first the spending required to maintain the existing business; then high-return organic reinvestment; then strategic acquisitions or divestitures; then balance-sheet decisions; and finally dividends or repurchases. For this industry, Humana investors should pay particular attention to whether management is reinvesting during peaks in the cycle, paying too much for acquired growth, underfunding maintenance, or returning capital while leverage or other obligations remain elevated. The useful question is not whether Humana “returns cash to shareholders.” It is whether each dollar has been directed to its highest credible risk-adjusted use. Measure outcomes over multi-year periods using per-share results, returns on invested capital, cash conversion, balance-sheet resilience, and the performance of acquired or newly built assets for Humana. Repurchases can destroy value if executed at poor prices or merely offset heavy dilution for Humana.

## Growth Drivers

Potential growth for Humana should be decomposed into observable mechanisms rather than summarized as a single forecast.

- **Membership Or Patient Volume:** verify management evidence, identify the KPI, separate organic improvement from acquisition/price/mix, and define a disconfirming signal.

- **Utilization:** verify management evidence, identify the KPI, separate organic improvement from acquisition/price/mix, and define a disconfirming signal.

- **Reimbursement Rates:** verify management evidence, identify the KPI, separate organic improvement from acquisition/price/mix, and define a disconfirming signal.

- **Medical Cost Trends:** verify management evidence, identify the KPI, separate organic improvement from acquisition/price/mix, and define a disconfirming signal.

- **Script Or Distribution Volume:** verify management evidence, identify the KPI, separate organic improvement from acquisition/price/mix, and define a disconfirming signal.

## Risk Factors

Use Humana's current risk disclosures to decide which of the following industry risks actually deserve prominence. Each retained risk needs a causal path and a warning signal.

- **Reimbursement Changes:** map the exposure to revenue, margin, cash flow, balance sheet, or strategic position; do not copy boilerplate risk language.

- **Medical-Cost Inflation:** map the exposure to revenue, margin, cash flow, balance sheet, or strategic position; do not copy boilerplate risk language.

- **Labor Shortages:** map the exposure to revenue, margin, cash flow, balance sheet, or strategic position; do not copy boilerplate risk language.

- **Regulation:** map the exposure to revenue, margin, cash flow, balance sheet, or strategic position; do not copy boilerplate risk language for Humana.

- **Utilization Spikes:** map the exposure to revenue, margin, cash flow, balance sheet, or strategic position; do not copy boilerplate risk language.

- **Pharmacy/Drug Pricing Pressure:** map the exposure to revenue, margin, cash flow, balance sheet, or strategic position; do not copy boilerplate risk language.

- **Execution Complexity:** map the exposure to revenue, margin, cash flow, balance sheet, or strategic position; do not copy boilerplate risk language.

## Bull, Base and Bear Operating Framework

**Bull operating case.** A favorable fundamental path for Humana would combine healthy membership or patient volume and utilization, stable or improving competitive position, disciplined reinvestment, and cost behavior that allows incremental revenue to convert efficiently into cash. This is not a share-price forecast. The purpose is to state what would have to go unusually well in the Humana business itself. **Base operating case.** A normal-execution path would show mixed but manageable movement in membership or patient volume, utilization, and reimbursement rates, no material erosion in the company’s key competitive mechanisms, and capital allocation consistent with the economics of the business. Results may still be cyclical; “base” does not mean smooth. **Bear operating case.** A deteriorating path would combine one or more of reimbursement changes, medical-cost inflation, labor shortages, and regulation with weaker operating indicators, pressure on margins or cash conversion, and reduced strategic flexibility. The bear framework should be updated when new filings reveal a different risk concentration for Humana.

## What Could Prove an Investment Thesis Wrong?

- **Persistent deterioration in membership or patient volume.** Define a numeric or filing-based threshold before relying on the thesis so the test is not moved after results disappoint.

- **Weakening membership or patient volume despite a healthy end market.** Define a numeric or filing-based threshold before relying on the thesis so the test is not moved after results disappoint.

- **Multi-period margin compression without a credible reinvestment explanation.** Define a numeric or filing-based threshold before relying on the thesis so the test is not moved after results disappoint for Humana.

- **Capital allocation that lowers per-share economics or raises balance-sheet risk.** Define a numeric or filing-based threshold before relying on the thesis so the test is not moved after results disappoint for Humana.

- **Evidence that customer switching costs, brand, network, cost position, or another claimed advantage is weaker than assumed.** Define a numeric or filing-based threshold before relying on the thesis so the test is not moved after results disappoint for Humana.

- **A structural industry change that makes historical comparisons misleading.** Define a numeric or filing-based threshold before relying on the thesis so the test is not moved after results disappoint for Humana.

## What Investors Commonly Misunderstand About This Company

- **GICS classification is not the whole company.** Humana is classified as Managed Health Care, but actual segments may span adjacent markets. Use segment disclosures.

- **Revenue growth is not automatically economic improvement.** Price, mix, acquisitions, FX, and accounting changes can produce growth with very different cash consequences for Humana.

- **The most visible product may not be the profit engine.** Verify which Humana business lines produce operating profit and cash rather than assuming brand visibility equals economic importance.

- **A strong cycle can masquerade as a stronger moat.** Compare performance with peers and end-market conditions before attributing all improvement to execution for Humana.

- **Free cash flow needs context.** Working-capital timing, deferred investment, restructuring, and stock compensation can make one period unusually strong or weak for Humana.

## What to Monitor

A practical Humana monitoring list should remain short enough to update every quarter. For each item, store the definition, historical series, source, and why a change would alter the Humana business thesis.

- **Membership Or Patient Volume:** record trend, management explanation, link to revenue/margin/cash flow, and a threshold that would trigger deeper review.

- **Medical Cost Ratio Where Relevant:** record trend, management explanation, link to revenue/margin/cash flow, and a threshold that would trigger deeper review.

- **Same-Facility Growth:** record trend, management explanation, link to revenue/margin/cash flow, and a threshold that would trigger deeper review.

- **Reimbursement/Payer Mix:** record trend, management explanation, link to revenue/margin/cash flow, and a threshold that would trigger deeper review.

- **Labor Cost:** record trend, management explanation, link to revenue/margin/cash flow, and a threshold that would trigger deeper review.

- **Script/Distribution Volume:** record trend, management explanation, link to revenue/margin/cash flow, and a threshold that would trigger deeper review.

- **Operating Margin:** record trend, management explanation, link to revenue/margin/cash flow, and a threshold that would trigger deeper review.

- **Membership Or Patient Volume:** record trend, management explanation, link to revenue/margin/cash flow, and a threshold that would trigger deeper review.

- **Utilization:** record trend, management explanation, link to revenue/margin/cash flow, and a threshold that would trigger deeper review.

- **Reimbursement Rates:** record trend, management explanation, link to revenue/margin/cash flow, and a threshold that would trigger deeper review.

## Questions Investors Should Ask

- What are Humana's actual reportable segments, and which segment contributes the most operating profit and cash?

- Which of membership or patient volume, utilization, and reimbursement rates explains most of Humana's revenue change?

- Is Humana's pricing power strengthening, stable, or weakening, and what evidence proves it?

- How much of recent growth is organic versus acquisition, FX, price, mix, or accounting change for Humana?

- What portion of reinvestment is maintenance versus growth?

- Which customer group has the strongest bargaining power and why?

- Are customer concentration or supplier concentration becoming more material?

- Which metric would deteriorate first if the competitive position weakened?

- Does operating leverage improve cash economics in growth periods without creating excessive downside in contractions for Humana?

- What is the most important balance-sheet constraint on strategy?

- How has management allocated incremental cash over the last full cycle for Humana?

- Have acquisitions improved per-share economics after considering price paid and dilution for Humana?

- Which regulatory change would most directly alter the business model?

- What macro variable has the clearest causal link to demand or margins for Humana?

- What evidence would make the current business-model classification obsolete?

## S&P 500 Equal Weight Index Context

As of the 2026-09-15 snapshot, Humana is one of 500 constituent companies represented by 503 security lines in the parent S&P 500 universe used by Swoopr. The S&P 500 Equal Weight Index uses the same constituent companies but resets companies to equal weight at quarterly rebalances for Humana. With 500 companies, the nominal company target is about 0.20% immediately after a rebalance, before market movement causes weights to drift for Humana. Humana therefore has materially different index influence in the equal-weight version than it may have in the capitalization-weighted S&P 500.

## Key Takeaways

- Humana is classified in Health Care / Managed Health Care; use that classification as a starting point, not a replacement for segment research.

- The most useful operating variables to verify are membership or patient volume, utilization, reimbursement rates, and medical cost trends.

- The cost structure should be analyzed around medical claims or clinical labor, purchased pharmaceuticals/supplies, facility expense, and technology.

- The most relevant monitoring metrics begin with membership or patient volume, medical cost ratio where relevant, same-facility growth, reimbursement/payer mix, and labor cost.

- Industry risks include reimbursement changes, medical-cost inflation, labor shortages, and regulation, but only issuer-specific evidence should determine final risk ranking.

- Cash generation must be evaluated after maintenance reinvestment, working-capital needs, dilution, and acquisition spending for Humana.

- Humana receives the same nominal company weight as every other constituent at an S&P 500 Equal Weight quarterly reset, subject to multi-class allocation rules.

## Frequently Asked Questions

What does Humana do?

Humana is classified by GICS in Managed Health Care. That means the company participates in an industry where businesses generally delivers, finances, administers, or distributes healthcare services and products across insurers, providers, patients, pharmacies, and care settings. For Humana’s exact segments, products, services and customer groups, read Item 1 (Business) of its latest annual report (Form 10-K) on SEC EDGAR.

How does Humana make money?

The primary analytical lens is a healthcare-services, managed-care, facility, pharmacy, or distribution model. Investors should map Humana's actual disclosed revenue lines to membership or patient volume, utilization, reimbursement rates, and medical cost trends and distinguish recurring, transactional, cyclical, regulated, or project-based economics as applicable.

What sector is Humana in?

Humana is classified in the Health Care sector and Managed Health Care sub-industry in the constituent snapshot used by Swoopr.

What metrics matter for Humana?

Metrics commonly used for companies in this industry include membership or patient volume, medical cost ratio where relevant, same-facility growth, reimbursement/payer mix, labor cost, and script/distribution volume. Focus on the metrics Humana reports consistently or that can be reliably calculated from its filings.

What are the main risks for Humana?

Risks common in this industry include reimbursement changes, medical-cost inflation, labor shortages, regulation, and utilization spikes. Humana's latest annual report (Form 10-K) and quarterly report (Form 10-Q) show which of these matter most to it now.

Who are Humana's competitors?

Current index peers in the same or adjacent classification include AbbVie, Abbott Laboratories, Agilent Technologies, Align Technology, and Amgen. This is a research peer set, not a claim of direct competition across every product for Humana.

What economic conditions affect Humana?

The strongest macro hypotheses to test are employment, healthcare utilization, government budgets, wage inflation, and demographics. Each should be retained only when there is a clear transmission mechanism to demand, pricing, costs, financing, or capital allocation for Humana.

Is Humana in the S&P 500 Equal Weight Index?

Yes. Humana is treated as a current company constituent in the 2026-09-15 snapshot because the Equal Weight Index uses the same constituent companies as the S&P 500.

What is Humana's target weight in the Equal Weight Index?

At a quarterly reset, each constituent company is assigned an equal company weight for Humana. With 500 companies, the nominal target is about 0.20% per company before weights drift with market movements for Humana.

Does Humana have multiple share classes in the index?

No multi-class treatment is recorded for this issuer in the current snapshot; Swoopr's registry records security line HUM.

How should an investor use this page?

Use the Humana dossier as an educational research map: identify the business model, verify the company-specific disclosures in primary sources, track a small set of causal operating metrics, and define thesis-breakers before relying on a conclusion.

Is this investment advice?

No. This dossier is educational research content. It does not provide individualized investment advice, a buy/sell recommendation, or a price target.

## References

1. [U.S. Securities and Exchange Commission: Humana filings](https://www.sec.gov/edgar/browse/?CIK=49071&owner=exclude)

Use the latest 10-K, 10-Q, 8-K, proxy statement, and applicable registration filings for company-specific operating facts.

1. [S&P Dow Jones Indices: S&P 500 Equal Weight Index](https://www.spglobal.com/spdji/en/indices/equity/sp-500-equal-weight-index/)

Use for index identity and official index documentation.

1. [S&P Dow Jones Indices: U.S. Indices Methodology](https://www.spglobal.com/spdji/en/documents/methodologies/methodology-sp-us-indices.pdf)

Use for equal-weight calculation, rebalancing, and multi-class treatment.

1. **Current constituent metadata snapshot used by Swoopr.** Swoopr's constituent registry records ticker, GICS classification, CIK, founding/lineage field, and S&P 500 addition date as of 2026-09-15.

## Editorial Verification Gate

Before this Humana dossier is marked GREEN, an editor or research agent must reconcile every issuer-specific narrative statement against the latest primary sources, populate actual segments and significant products, add current as-of-dated financial and operating metrics where useful, verify management and geography, expand the company timeline with sourced events, and replace any industry hypothesis that does not apply to the issuer. This gate is intentionally explicit: completeness of page structure must never be mistaken for verification of current financial facts.

## More in This Section

- [Humana History & Investor Timeline](https://www.getswoopr.com/stocks/companies/humana/history-timeline/)
- [Humana in the S&P 500 Equal Weight Index](https://www.getswoopr.com/stocks/companies/humana/equal-weight-membership/)
- [Humana Industry Context](https://www.getswoopr.com/stocks/companies/humana/industry-context/)
- [Humana Monitoring Guide](https://www.getswoopr.com/stocks/companies/humana/monitoring-guide/)
- [Humana: Business Model & Revenue Engine](https://www.getswoopr.com/stocks/companies/humana/business-model/)
- [Humana: Competitors & Industry Structure](https://www.getswoopr.com/stocks/companies/humana/competitors/)
- [Humana: History & Research Timeline](https://www.getswoopr.com/stocks/companies/humana/history/)
- [Humana: Metrics Guide](https://www.getswoopr.com/stocks/companies/humana/metrics/)
- [Humana: Risk & Monitoring Guide](https://www.getswoopr.com/stocks/companies/humana/risks/)

**[Swoopr Editorial Team](https://www.getswoopr.com/authors/swoopr-editorial-team/)**

Swoopr's editorial team produces independent investment education content reviewed for accuracy and clarity. We do not provide personalized financial advice. See our [editorial policy](https://www.getswoopr.com/legal/editorial-policy/) and [corrections policy](https://www.getswoopr.com/legal/corrections-policy/).